Is TransMedics Group, Inc. (TMDX) Stock Still a MedTech Growth Opportunity After Analyst Target Cut?
TheFly reported on July 6 that Evercore ISI analyst Daniel Markowitz reduced the price target on TMDX to $90 from $100 while maintaining an Outperform rating on the shares.






